• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-21

  Zhou et al. identify TSPAN18 as a regulator of STIM1 stability, showing that it protects STIM1 from TRIM32-mediated ubiquitination and sustains calcium entry linked to prostate cancer bone metastasis. The study connects protein-protection mechanisms with metastatic behavior and provides a framework for investigating the TSPAN18–STIM1–Ca2+ axis in follow-up models.

• Vardenafil HCl Trihydrate for Proteoform PDE5 Research

  2026-09-21

  Vardenafil HCl Trihydrate supports a connected workflow spanning PDE5 inhibition, cGMP signaling, smooth muscle assays, and proteoform-aware off-target analysis. Its strong PDE5 potency and defined PDE isoform selectivity make it useful for separating target biology from PDE6-related observations in native membrane systems.

• Direct Mouse Genotyping Kit Plus for Atherosclerosis

  2026-09-20

  Build faster, purification-free mouse genotyping workflows for transgene screening, knockout validation, and complex atherosclerosis cohorts. The Direct Mouse Genotyping Kit Plus combines direct tissue lysate preparation with a dye-containing high-fidelity PCR mix, helping laboratories connect genotype assignments to macrophage and plaque phenotypes with fewer handling steps.

• TCF25 Links V-ATPase to Lysosomal Cell Death

  2026-09-19

  Ren et al. identify TCF25 as a nutrient sensor that couples glucose-starvation adaptation to lysosome-dependent cell death by regulating V-ATPase-associated acidification. Their CRISPR-Cas9, mechanistic, and mouse ischemia-reperfusion studies define a context-dependent lysosomal pathway with implications for metabolic stress research.

• Concanamycin A: V-ATPase Assay Workflows

  2026-09-18

  Build sharper lysosomal-stress and tumor-cell assays with Concanamycin A, a nanomolar V-type H+-ATPase inhibitor for dissecting acidification, trafficking, apoptosis, and invasion. This workflow connects acute V-ATPase inhibition to the AMPK–SQSTM1/p62–NRF2 stress circuitry highlighted in recent cancer biology research.

• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-09-18

  This 2024 Nature Communications study identifies SmD2 acetylation as a regulatory connection between core spliceosome activity, BRCA1/FANC cassette exons, and DNA-damage repair in hepatocellular carcinoma. The work shows that SmD2 depletion or HDAC-inhibitor treatment can increase sensitivity to PARP inhibition, providing a mechanistic rationale for combination treatment in HCC models.

• Abiraterone Acetate in Translational Prostate Cancer

  2026-09-17

  A thought-leadership guide to using Abiraterone acetate as a CYP17 inhibitor in prostate cancer research, with strategic lessons from patient-derived three-dimensional spheroids, model selection, assay design, and translational interpretation.

• MDV3100 in Enzalutamide Resistance Research

  2026-09-17

  MDV3100 enables more than a viability readout: it connects androgen receptor blockade with glycan remodeling, motility, spheroid growth, and therapeutic resistance. This workflow shows how to use Enzalutamide in prostate cancer models while separating acute AR responses from durable metabolic and phenotypic adaptations.

• LY2228820: Practical p38 MAPK Workflow Guide

  2026-09-16

  LY2228820 enables mechanism-focused studies of inflammatory signaling, tumor-cell stress, and angiogenic responses through selective p38α/β inhibition. This workflow guide connects target engagement, phosphatase-aware assay design, combination testing, and troubleshooting for more interpretable preclinical data.

• Lenalidomide (CC-5013): Assay Logic in Myeloma

  2026-09-16

  Explore how Lenalidomide (CC-5013) connects immunomodulation, tumor-cell stress, and innate immune signaling in multiple myeloma research. This evidence-led guide translates recent DOT1L findings into practical assay-design decisions while distinguishing established biology from combination-study hypotheses.

• Oltipraz for Reliable Nrf2 Assays

  2026-09-15

  A scenario-based guide to using Oltipraz (SKU B5958) in cell viability, cytotoxicity, and Nrf2-pathway experiments. It connects solvent control, dose selection, assay interpretation, and MASLD-related ferroptosis research to practical laboratory decisions.

• Machine Learning Prediction of mRNA Vaccine LNPs

  2026-09-15

  The reference study developed a LightGBM model to predict lipid nanoparticle formulations for mRNA vaccines from 325 formulation records, achieving an R² greater than 0.87. Experimental comparison of MC3 and SM-102, together with molecular dynamics modeling, connected computational prediction with biological performance and LNP structural behavior.

• DiscoveryProbe FDA-approved Drug Library Workflow

  2026-09-14

  Turn clinically characterized compounds into a structured workflow for target discovery, phenotypic screening, and drug repositioning screening. The library combines screening-ready DMSO stocks with an iterative assay-to-model strategy that can expose both expected pharmacology and useful off-target biology.

• SmD2 Acetylation and PARP Sensitivity in HCC

  2026-09-14

  The reference study identifies SmD2 as an acetylation-sensitive core spliceosome component that links alternative splicing, DNA-damage repair, and PARP inhibitor response in hepatocellular carcinoma. Its findings support a mechanistic rationale for combining HDAC-directed treatment with PARP inhibition, while also defining important limits for translating the work to other HDAC inhibitors and cancer models.

• Vitamin C Beyond Cancer: Organoid Translation

  2026-09-13

  A translational framework for using Vitamin C ascorbic acid in cancer research while assessing how multilineage organoids can clarify antiviral opportunities, model limitations, and next-step experimental strategy.

8543 records 1/570 page Next 12345 下5页 Last page